Deep knowledge of your business's most important issues.

IP Due Diligence Assessment of Cell-Based Therapy

Led an IP due diligence team and assisted in drafting portions of the license agreement between a life sciences company and a cell-based therapy company. The technology involved complex cell-based therapy useful in treating critical limb ischemia, requiring a difficult freedom to operate assessment of highly entangled IP in an area where many cross-licenses exist. The deal received the Deal of Distinction Award by the Licensing Executives Society.